Guggenheim Raises Regeneron Price Target to $975 as 36 Immunology Abstracts Unveil Phase 3 Data
RBC maintained a Hold rating on Regeneron with a $745 price target, while Guggenheim raised its target to $975 and retained a Buy outlook. It will present 36 abstracts, including novel Phase 3 ocular allergy programs for cat and birch plus Dupixent analyses in dermatological, respiratory and gastrointestinal diseases.
1. Analyst Ratings and Price Targets
RBC maintained a Hold rating on Regeneron with a $745 price target, while Guggenheim boosted its target to $975 and upheld a Buy rating after revising its financial model post-earnings.
2. Immunology Abstracts at AAAAI Meeting
Regeneron will present 36 abstracts at the American Academy of Allergy, Asthma and Immunology meeting from February 27 to March 2, featuring first Phase 3 allergen-specific ocular symptom programs for cat and birch allergies and new Dupixent analyses across dermatological, respiratory and gastrointestinal indications.
3. Upcoming Pipeline Catalysts
Key potential catalysts include fianlimab/Libtayo LAG-3 melanoma trial results, an FDA decision on Eylea HD pre-filled syringe in Q2, and a planned cemdisiran NDA submission for generalized myasthenia gravis in Q1.